Down-regulation of human leukocyte antigen class I (HLA-I) is associated with poor prognosis in patients with clear cell renal cell carcinoma

Acta Histochemica

Volumn 115, Issue 5, 2013, Pages 470-474

  Yuan, Jinyang ^a   Liu, Sulai ^a   Yu, Qiuxia ^a   Lin, Yang ^a   Bi, Yunke ^a   Wang, Yi ^a   An, Ruihua ^a  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Clear cell renal cell carcinoma; Human; Human leukocyte antigen class I; Immunohistochemistry; Prognosis

Indexed keywords

HLA ANTIGEN CLASS 1;

ADULT; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIMARY TUMOR; SURVIVAL TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CHINA; DOWN-REGULATION; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84879845025     PISSN: 00651281     EISSN: 16180372     Source Type: Journal    
DOI: 10.1016/j.acthis.2012.11.002     Document Type: Article

References (32)

1. Andersson E., Villabona L., Bergfeldt K., Carlson J.W., Ferrone S., Kiessling R., et al. Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer. Cancer Immunol Immunother 2012, 61:1243-1253.
2. Atkins D., Ferrone S., Schmahl G.E., Storkel S., Seliger B. Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma?. J Urol 2004, 171:885-889.
3. Esteban F., Redondo M., Delgado M., Garrido F., Ruiz-Cabello F. MHC class I antigens and tumour-infiltrating leucocytes in laryngeal cancer: long-term follow-up. Br J Cancer 1996, 74:1801-1804.
4. Garrido F., Cabrera T., Concha A., Glew S., Ruiz-Cabello F., Stern P.L. Natural history of HLA expression during tumour development. Immunol Today 1993, 14:491-499.
5. Garrido F., Ruiz-Cabello F., Cabrera T., Perez-Villar J.J., Lopez-Botet M., Duggan-Keen M., et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997, 18:89-95.
6. Grimm M.O., Wolff I., Zastrow S., Frohner M., Wirth M. Advances in renal cell carcinoma treatment. Ther Adv Urol 2010, 2:11-17.
7. Gudmundsdottir I., Gunnlaugur Jonasson J., Sigurdsson H., Olafsdottir K., Tryggvadottir L., Ogmundsdottir H.M. Altered expression of HLA class I antigens in breast cancer: association with prognosis. Int J Cancer 2000, 89:500-505.
8. Gupta K., Miller J.D., Li J.Z., Russell M.W., Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 2008, 34:193-205.
9. Hsieh C.H., Hsu Y.J., Chang C.C., Liu H.C., Chuang K.L., Chuang C.K., et al. class I loss in a sarcomatoid renal carcinoma cell line caused by the coexistence of distinct mutations in the two encoding beta2-microglobulin genes. Cancer Immunol Immunother 2009, 58:395-408.
10. Kaneko K., Ishigami S., Kijima Y., Funasako Y., Hirata M., Okumura H., et al. Clinical implication of HLA class I expression in breast cancer. BMC Cancer 2011, 11:454.
11. Kikuchi E., Yamazaki K., Torigoe T., Cho Y., Miyamoto M., Oizumi S., et al. HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer. Cancer Sci 2007, 98:1424-1430.
12. Kitamura H., Honma I., Torigoe T., Asanuma H., Sato N., Tsukamoto T. Down-regulation of HLA class I antigen is an independent prognostic factor for clear cell renal cell carcinoma. J Urol 2007, 177:1269-1272. discussion, p. 1272.
13. Krishnakumar S., Sundaram A., Abhyankar D., Krishnamurthy V., Shanmugam M.P., Gopal L., et al. Major histocompatibility antigens and antigen-processing molecules in retinoblastoma. Cancer 2004, 100:1059-1069.
14. Leibovich B.C., Lohse C.M., Crispen P.L., Boorjian S.A., Thompson R.H., Blute M.L., et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol 2010, 183:1309-1315.
15. Ljunggren H.G., Karre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 1990, 11:237-244.
16. Madjd Z., Spendlove I., Pinder S.E., Ellis I.O., Durrant L.G. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer 2005, 117:248-255.
17. Menon A.G., Morreau H., Tollenaar R.A., Alphenaar E., Van Puijenbroek M., Putter H., et al. Down-regulation of HLA - a expression correlates with a better prognosis in colorectal cancer patients. Lab Invest 2002, 82:1725-1733.
18. Mizukami Y., Kono K., Maruyama T., Watanabe M., Kawaguchi Y., Kamimura K., et al. Downregulation of HLA Class I molecules in the tumour is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma. Br J Cancer 2008, 99:1462-1467.
19. Morrison L.A., Lukacher A.E., Braciale V.L., Fan D.P., Braciale T.J. Differences in antigen presentation to MHC class I-and class II-restricted influenza virus-specific cytolytic T lymphocyte clones. J Exp Med 1986, 163:903-921.
20. Ramnath N., Tan D., Li Q., Hylander B.L., Bogner P., Ryes L., et al. Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival?. Cancer Immunol Immunother 2006, 55:891-899.
21. Rini B.I., Campbell S.C., Escudier B. Renal cell carcinoma. Lancet 2009, 373:1119-1132.
22. Seliger B. Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. Cancer Immunol Immunother 2008, 57:1719-1726.
23. Speetjens F.M., de Bruin E.C., Morreau H., Zeestraten E.C., Putter H., van Krieken J.H., et al. Clinical impact of HLA class I expression in rectal cancer. Cancer Immunol Immunother 2008, 57:601-609.
24. Tanaka K., Tsuchikawa T., Miyamoto M., Maki T., Ichinokawa M., Kubota K.C., et al. Down-regulation of Human Leukocyte Antigen class I heavy chain in tumors is associated with a poor prognosis in advanced esophageal cancer patients. Int J Oncol 2012, 40:965-974.
25. Torigoe T., Asanuma H., Nakazawa E., Tamura Y., Hirohashi Y., Yamamoto E., et al. Establishment of a monoclonal anti-pan HLA class I antibody suitable for immunostaining of formalin-fixed tissue: unusually high frequency of down-regulation in breast cancer tissues. Pathol Int 2012, 62:303-308.
26. Townsend A.R., Rothbard J., Gotch F.M., Bahadur G., Wraith D., McMichael A.J. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 1986, 44:959-968.
27. Tsukahara T., Kawaguchi S., Torigoe T., Asanuma H., Nakazawa E., Shimozawa K., et al. Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5. Cancer Sci 2006, 97:1374-1380.
28. Ueda Y., Ishikawa K., Shiraishi N., Yokoyama S., Kitano S. Clinical significance of HLA class I heavy chain expression in patients with gastric cancer. J Surg Oncol 2008, 97:451-455.
29. van Driel W.J., Tjiong M.Y., Hilders C.G., Trimbos B.J., Fleuren G.J. Association of allele-specific HLA expression and histopathologic progression of cervical carcinoma. Gynecol Oncol 1996, 62:33-41.
30. Vitale M., Pelusi G., Taroni B., Gobbi G., Micheloni C., Rezzani R., et al. HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. Clin Cancer Res 2005, 11:67-72.
31. Yabe H., Tsukahara T., Kawaguchi S., Wada T., Torigoe T., Sato N., et al. Prognostic significance of HLA class I expression in Ewing's sarcoma family of tumors. J Surg Oncol 2011, 103:380-385.
32. Ye Q., Shen Y., Wang X., Yang J., Miao F., Shen C., et al. Hypermethylation of HLA class I gene is associated with HLA class I down-regulation in human gastric cancer. Tissue Antigens 2010, 75:30-39.